CA3092315C - Crystal form and salt form of pyridopyrazole compound and preparation method therefor - Google Patents

Crystal form and salt form of pyridopyrazole compound and preparation method therefor Download PDF

Info

Publication number
CA3092315C
CA3092315C CA3092315A CA3092315A CA3092315C CA 3092315 C CA3092315 C CA 3092315C CA 3092315 A CA3092315 A CA 3092315A CA 3092315 A CA3092315 A CA 3092315A CA 3092315 C CA3092315 C CA 3092315C
Authority
CA
Canada
Prior art keywords
compound
crystal form
formula
pattern
xrpd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3092315A
Other languages
English (en)
French (fr)
Other versions
CA3092315A1 (en
Inventor
Jian Xiong
Xiaoxin Chen
Jingjing Wang
Zhuowei LIU
Kevin X Chen
Chengwu Liu
Cheng Xie
Chaofeng LONG
Peng Li
Jian Li
Shuhui Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong Raynovent Biotech Co Ltd
Original Assignee
Guangdong Raynovent Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangdong Raynovent Biotech Co Ltd filed Critical Guangdong Raynovent Biotech Co Ltd
Publication of CA3092315A1 publication Critical patent/CA3092315A1/en
Application granted granted Critical
Publication of CA3092315C publication Critical patent/CA3092315C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA3092315A 2018-03-05 2019-03-05 Crystal form and salt form of pyridopyrazole compound and preparation method therefor Active CA3092315C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810180641.8 2018-03-05
CN201810180641 2018-03-05
PCT/CN2019/076916 WO2019170067A1 (zh) 2018-03-05 2019-03-05 一种吡啶并咪唑类化合物的晶型、盐型及其制备方法

Publications (2)

Publication Number Publication Date
CA3092315A1 CA3092315A1 (en) 2019-09-12
CA3092315C true CA3092315C (en) 2023-08-29

Family

ID=67846865

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3092315A Active CA3092315C (en) 2018-03-05 2019-03-05 Crystal form and salt form of pyridopyrazole compound and preparation method therefor

Country Status (11)

Country Link
US (1) US11535613B2 (https=)
EP (1) EP3763713A4 (https=)
JP (1) JP7031002B2 (https=)
KR (1) KR102484804B1 (https=)
CN (1) CN111819177B (https=)
AU (1) AU2019230497B2 (https=)
CA (1) CA3092315C (https=)
NZ (1) NZ767352A (https=)
RU (1) RU2769050C1 (https=)
TW (1) TWI794433B (https=)
WO (1) WO2019170067A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2727772C1 (ru) * 2016-09-05 2020-07-23 Гуандун Рэйновент Байотек Ко., Лтд. Производные пиримидина против вируса гриппа
WO2021012864A1 (zh) * 2019-07-22 2021-01-28 广东众生睿创生物科技有限公司 嘧啶衍生物的优势盐型及其晶型
WO2021047437A1 (zh) * 2019-09-10 2021-03-18 广东众生睿创生物科技有限公司 一种用于治疗病毒性感冒的药物组合物及其制剂
CN113116899B (zh) * 2020-03-06 2022-12-20 广东众生睿创生物科技有限公司 一种用于治疗流感的药物组合物及含有该药物组合物的制剂
WO2022089261A1 (zh) * 2020-10-29 2022-05-05 广东众生睿创生物科技有限公司 一种嘧啶衍生物的晶型及其制备方法
EP4286386A4 (en) * 2021-02-03 2025-03-12 Ocumension Therapeutics (Suzhou) Co., Ltd. Salt form and crystal form of a pyrazole-substituted imidazo[1,2-a]quinoxaline derivative
CN116829539B (zh) * 2021-03-11 2025-11-25 上海济煜医药科技股份有限公司 吡啶氮氧化合物晶型及其应用
WO2025237212A1 (zh) * 2024-05-11 2025-11-20 广东众生睿创生物科技有限公司 一种嘧啶衍生物葡甲胺盐及其晶型

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3141252T (lt) 2009-06-17 2018-11-12 Vertex Pharmaceuticals Inc. Gripo virusų replikacijos inhibitoriai
RU2013132681A (ru) 2010-12-16 2015-01-27 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы репликации вирусов гриппа
US8476281B2 (en) * 2011-01-14 2013-07-02 Vertex Pharmaceuticals Incorporated Solid forms of gyrase inhibitor (R)-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl)-1H-benzimidazol-2-yl]urea
CN106573920B (zh) * 2014-08-08 2020-11-10 爱尔兰詹森科学公司 用于在流感病毒感染中使用的吲哚
SG11201804225PA (en) * 2015-12-09 2018-06-28 Sunshine Lake Pharma Co Ltd Inhibitors of influenza virus replication, application methods and uses thereof
WO2017133670A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza
WO2017133667A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyrimidine and pyridine derivatives and use in treatment, amelioration or prevention of influenza thereof
AU2017229114B2 (en) * 2016-03-07 2023-01-12 HyTech Power, Inc. A method of generating and distributing a second fuel for an internal combustion engine
RU2727772C1 (ru) 2016-09-05 2020-07-23 Гуандун Рэйновент Байотек Ко., Лтд. Производные пиримидина против вируса гриппа

Also Published As

Publication number Publication date
US20200407354A1 (en) 2020-12-31
CN111819177B (zh) 2022-03-04
RU2769050C1 (ru) 2022-03-28
CA3092315A1 (en) 2019-09-12
US11535613B2 (en) 2022-12-27
WO2019170067A1 (zh) 2019-09-12
KR20200124710A (ko) 2020-11-03
JP7031002B2 (ja) 2022-03-07
EP3763713A4 (en) 2021-11-24
KR102484804B1 (ko) 2023-01-04
TW201938558A (zh) 2019-10-01
AU2019230497A1 (en) 2020-09-17
CN111819177A (zh) 2020-10-23
NZ767352A (en) 2023-05-26
TWI794433B (zh) 2023-03-01
AU2019230497B2 (en) 2021-08-05
EP3763713A1 (en) 2021-01-13
JP2021514967A (ja) 2021-06-17

Similar Documents

Publication Publication Date Title
CA3092315C (en) Crystal form and salt form of pyridopyrazole compound and preparation method therefor
CN113260613B (zh) 一种egfr抑制剂的盐、晶型及其制备方法
CN109071567B (zh) 抗流感小分子化合物及其制备方法和用途
JP2009515887A (ja) 神経系疾患のための治療薬としてのヒストンデアセチラーゼ阻害剤
JP7206241B2 (ja) 抗ウイルス薬および抗ウイルス薬の使用
US20110065762A1 (en) Methods of use of antiviral compounds
EP3992192B1 (en) Dominant salt forms of pyrimidine derivatives, and crystal forms thereof
JP6857617B2 (ja) インフルエンザウイルスの複製の阻害剤
CN112771048B (zh) 流感病毒复制抑制剂及其中间体和用途
CN106478760B (zh) 具有抗肿瘤作用的三帖类衍生物tba-x及其制备方法和应用
CN102329245A (zh) 具有抗禽流感病毒活性的金刚烷衍生物及其制备方法
CN101906056B (zh) 作为m2抑制剂的环烷胺类化合物及其应用
HK40030970A (en) Crystal form and salt form of pyridoimidazole compound and preparation method therefor
HK40030970B (zh) 一种吡啶并咪唑类化合物的晶型、盐型及其制备方法
CN101775007B (zh) 具有hiv拮抗活性的三环烯类化合物及其制备方法与应用
RU2552422C2 (ru) Производные индол-3-карбоновой кислоты, обладающие противовирусной активностью
CN107286115B (zh) N-(5-芳甲基噻唑-2-基)哌嗪基酰胺及其作为na抑制剂的应用
CN104151256B (zh) 二取代苯甲酰胺类化合物及其合成方法和应用
WO2024098856A1 (zh) 一种抗流感病毒衍生物及其用途
CN114773267A (zh) [(7-三氟甲基喹啉-4-基)氨基]苯甲酰胺类化合物及其制备与应用
CN107304180B (zh) 苯甲酰胺类衍生物、其制备方法及其在医药上的用途
CN104803877B (zh) 一种o‑苯乙酰‑(4‑三氟甲基)水杨酰胺类化合物及其应用
CN117946165A (zh) 一种新型结构化合物axl抑制剂及其应用
CN107235927A (zh) N‑(5‑酰基噻唑‑2‑基)哌嗪基酰胺及其医药用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220928

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250220

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250220

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250220

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260223

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260223